Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by classical motor features of parkinsonism associated with the loss of dopaminergic neurons in the substantia nigra and dopamine deficiency. The classical motor symptoms of PD include bradykinesia, rest tremor, muscular rigidity and postural impairment. Apart from the typical motor symptoms, PD is characterized by a wide range of different non-motoric symptoms like depression, dementia, speech disorders, sleep disorders and autonomic dysfunction. Clinical diagnosis of PD is based on the presence of parkinsonian motor features and dopaminergic imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT) are used to confirm the diagnosis and to distinguish PD from other similar diseases. Available medications for PD only treat symptoms of the disease trying to control motor features and to improve the quality of life of patients. Parkinson’s rating scales have an important role in clinical practice. They are used to assess the degree of disease-related disability, for monitoring and predicting further progression of the disease and to help to evaluate the efficiency of the therapeutic procedures. Generally, they can be divided into those related to motor manifestations and to those evaluating non-motoric symptoms. However, the best results and an accurate insight into the patient's health condition can only be obtained by their combination. The most well established and widely used rating scale is the Unified Parkinson's Disease Rating Scale – UPDRS, which combines elements of both motor and nonmotor scales. Many clinical trials have proven that the UPDRS demonstrates high internal consistency and reliability, shows moderate to good validity and has a stable factor structure. The second two most used rating scales are the Hoehn-Yahr Scale (HY) and Schwab and England Scale (SE-ADL), which demonstrate similar validity and reliability as the UPDRS.